---
title: "Biperiden - Parkinsonian Disorders"
sidebar: mydoc_sidebar
permalink: db00810-mesh-d020734-1.html
toc: false 
---


Path ID: `DB00810_MESH_D020734_1`
{% include image.html url="images/db00810-mesh-d020734-1.png" file="db00810-mesh-d020734-1.png" alt="db00810-mesh-d020734-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D001712 | biperiden | Drug |
| UniProt:P11229 | Muscarinic acetylcholine receptor M1 | Protein |
| GO:0007271 | synaptic transmission, cholinergic | BiologicalProcess |
| HP:0100022 | Abnormality of movement | PhenotypicFeature |
| MESH:D020734 | Parkinsonian Disorders | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Biperiden | NEGATIVELY REGULATES | Muscarinic Acetylcholine Receptor M1 |
| Muscarinic Acetylcholine Receptor M1 | POSITIVELY REGULATES | Synaptic Transmission, Cholinergic |
| Synaptic Transmission, Cholinergic | POSITIVELY CORRELATED WITH | Abnormality Of Movement |
| Abnormality Of Movement | MANIFESTATION OF | Parkinsonian Disorders |
|---------|-----------|---------|

Comment: The disease is also known as Parkinsonism as per the original file. Muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).

Reference: 
  - [https://go.drugbank.com/drugs/DB00810#mechanism-of-action](https://go.drugbank.com/drugs/DB00810#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects](https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects)
